Debasish Tripathy, M.D.

Peer-Reviewed Articles

1. Ring A, Mineyev N, Zhu W, Park E, Lomas C, Punj V, Yu M, Barrak D, Forte V, Porras T, Tripathy D, Lang JE. EpCAM based capture detects and recovers circulating tumor cells from all subtypes of breast cancer except claudin-low. Oncotarget 6(42):44623-34, 2015. e-Pub 2015. PMID: 26556851.
2. Kai K, Kondo K, Wang X, Xie X, Pitner MK, Reyes ME, Torres-Adorno AM, Masuda H, Hortobagyi GN, Bartholomeusz C, Saya H, Tripathy D, Sen S, Ueno NT. Antitumor Activity of KW-2450 Against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases. Mol Cancer Ther 14(12):2687-99, 2015. e-Pub 2015. PMID: 26443806.
3. Silberman H, Sheth PA, Parisky YR, Hovanessian-Larsen LJ, Sheth S, Tripathy D. Modified Bi-Rads Scoring of Breast Imaging Findings Improves Clinical Judgment. Breast J 21(6):642-50, 2015. e-Pub 2015. PMID: 26411901.
4. Subbiah IM, Lei X, Weinberg JS, Sulman EP, Chavez-MacGregor M, Tripathy D, Gupta R, Varma A, Chouhan J, Guevarra RP, Valero V, Gilbert MR, Gonzalez-Angulo AM. Validation and Development of a Modified Breast Graded Prognostic Assessment As a Tool for Survival in Patients With Breast Cancer and Brain Metastases. J Clin Oncol 33(20):2239-45, 2015. e-Pub 2015. PMID: 25987700.
5. DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. Clin Cancer Res 21(13):2911-5, 2015. e-Pub 2015. PMID: 25712686.
6. Poole BB, Wecsler JS, Sheth P, Sener SF, Wang L, Larsen L, Tripathy D, Lang JE. Malignancy rates after surgical excision of discordant breast biopsies. J Surg Res 195(1):152-7, 2015. e-Pub 2014. PMID: 25519987.
7. Liu S, Meric-Bernstam F, Parinyanitikul N, Wang B, Eterovic AK, Zheng X, Gagea M, Chavez-MacGregor M, Ueno NT, Lei X, Zhou W, Nair L, Tripathy D, Brown PH, Hortobagyi GN, Chen K, Mendelsohn J, Mills GB, Gonzalez-Angulo AM. Functional consequence of the MET-T1010I polymorphism in breast cancer. Oncotarget 6(5):2604-14, 2015. PMID: 25605252.
8. Lang JE, Wecsler JS, Press MF, Tripathy D. Molecular markers for breast cancer diagnosis, prognosis and targeted therapy. J Surg Oncol 111(1):81-90, 2015. e-Pub 2014. PMID: 25091830.
9. Elsayegh N, Profato J, Barrera AM, Lin H, Kuerer HM, Ardic C, Litton JK, Tripathy D, Arun BK. Predictors that Influence Election of Contralateral Prophylactic Mastectomy among Women with Ductal Carcinoma in Situ who are BRCA-Negative. J Cancer 6(7):610-5, 2015. e-Pub 2015. PMID: 26078790.
10. Lang JE, Scott JH, Wolf DM, Novak P, Punj V, Magbanua MJ, Zhu W, Mineyev N, Haqq CM, Crothers JR, Esserman LJ, Tripathy D, van 't Veer L, Park JW. Expression profiling of circulating tumor cells in metastatic breast cancer. Breast Cancer Res Treat 149(1):121-31, 2015. e-Pub 2014. PMID: 25432738.
11. Yang-Kolodji G, Mumenthaler SM, Mehta A, Ji L, Tripathy D. Phosphorylated ribosomal S6 (p-rpS6) as a post-treatment indicator of HER2 signalling targeted drug resistance. Biomarkers 20(5):313-22, 2015. PMID: 26329528.
12. Greenlee H, Balneaves LG, Carlson LE, Cohen M, Deng G, Hershman D, Mumber M, Perlmutter J, Seely D, Sen A, Zick SM, Tripathy D, Society for Integrative Oncology. Clinical practice guidelines on the use of integrative therapies as supportive care in patients treated for breast cancer. J Natl Cancer Inst Monogr 2014(50):346-58, 2014. PMID: 25749602.
13. Tripathy D, Durie BG, Mautner B, Ferenz KS, Moul JW. Awareness, concern, and communication between physicians and patients on bone health in cancer. Support Care Cancer 22(6):1601-10, 2014. e-Pub 2014. PMID: 24477326.
14. Yardley DA, Kaufman PA, Brufsky A, Yood MU, Rugo H, Mayer M, Quah C, Yoo B, Tripathy D. Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer. Breast Cancer Res Treat 145(3):725-34, 2014. e-Pub 2014. PMID: 24706168.
15. Yardley DA, Tripathy D, Brufsky AM, Rugo HS, Kaufman PA, Mayer M, Magidson J, Yoo B, Quah C, Ulcickas Yood M. Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER. Br J Cancer 110(11):2756-64, 2014. e-Pub 2014. PMID: 24743708.
16. Lang JE,Wecsler JS,Press MF,Tripathy D. Molecular markers for breast cancer diagnosis,prognosis and targeted therapy, 2014. e-Pub 2014. PMID: 25091830.
17. Kim M, Agarwal S, Tripathy D. Updates on the treatment of human epidermal growth factor receptor type 2-positive breast cancer. Curr Opin Obstet Gynecol 26(1):27-33, 2014. PMID: 24335887.
18. Mehta A, Tripathy D. Co-targeting estrogen receptor and HER2 pathways in breast cancer. Breast 23(1):2-9, 2014. e-Pub 2013. PMID: 24176518.
19. Tripathy D, Rugo HS, Kaufman PA, Swain S, O'Shaughnessy J, Jahanzeb M, Mason G, Beattie M, Yoo B, Lai C, Masaquel A, Hurvitz S. The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. BMC Cancer 14:307, 2014. e-Pub 2014. PMID: 24885258.
20. Rugo HS, Brufsky AM, Ulcickas Yood M, Tripathy D, Kaufman PA, Mayer M, Yoo B, Abidoye OO, Yardley DA. Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat 141(3):461-70, 2013. e-Pub 2013. PMID: 24062208.
21. DeMichele A, Berry DA, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski JE, Kelloff G, Perlmutter J, Buxton M, Lyandres J, Albain KS, Benz C, Chien AJ, Haluska P, Leyland-Jones B, Liu MC, Munster P, Olopade O, Park JW, Parker BA, Pusztai L, Tripathy D, Rugo H, Yee D, Esserman L. Developing safety criteria for introducing new agents into neoadjuvant trials. Clin Cancer Res 19(11):2817-23, 2013. e-Pub 2013. PMID: 23470967.
22. Jiang L, Weatherall PT, McColl RW, Tripathy D, Mason RP. Blood oxygenation level-dependent (BOLD) contrast magnetic resonance imaging (MRI) for prediction of breast cancer chemotherapy response: a pilot study. J Magn Reson Imaging 37(5):1083-92, 2013. e-Pub 2012. PMID: 23124705.
23. Tripathy D, Kaufman PA, Brufsky AM, Mayer M, Yood MU, Yoo B, Quah C, Yardley D, Rugo HS. First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER. Oncologist 18(5):501-10, 2013. e-Pub 2013. PMID: 23652380.
24. Baniwal SK, Chimge NO, Jordan VC, Tripathy D, Frenkel B. Prolactin-induced protein (PIP) regulates proliferation of luminal A type breast cancer cells in an estrogen-independent manner. PLoS One 8(6):e62361, 2013. e-Pub 2013. PMID: 23755096.
25. Yee D, Haddad T, Albain K, Barker A, Benz C, Boughey J, Buxton M, Chien AJ, DeMichele A, Dilts D, Elias A, Haluska P, Hogarth M, Hu A, Hytlon N, Kaplan HG, Kelloff GG, Khan Q, Lang J, Leyland-Jones B, Liu M, Nanda R, Northfelt D, Olopade OI, Park J, Parker B, Parkinson D, Pearson-White S, Perlmutter J, Pusztai L, Symmans F, Rugo H, Tripathy D, Wallace A, Wholley D, Van't Veer L, Berry DA, Esserman L. Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development. J Clin Oncol 30(36):4584-6; author reply 4588-9, 2012. e-Pub 2012. PMID: 23169510.
26. Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, van 't Veer L, Hylton N. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol 30(26):3242-9, 2012. e-Pub 2012. PMID: 22649152.
27. Tripathy D. Breast cancer quality care: what is at stake?. Breast J 18(3):201-2, 2012. PMID: 22583193.
28. Lin C, Buxton MB, Moore D, Krontiras H, Carey L, DeMichele A, Montgomery L, Tripathy D, Lehman C, Liu M, Olapade O, Yau C, Berry D, Esserman LJ, I-SPY TRIAL Investigators. Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial). Breast Cancer Res Treat 132(3):871-9, 2012. e-Pub 2011. PMID: 21796368.
29. Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, Wolf D, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Livasy C, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, Au A, Hylton N, I-SPY 1 TRIAL Investigators. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 132(3):1049-62, 2012. e-Pub 2011. PMID: 22198468.
30. Tripathy D. Using neoadjuvant therapy for breast cancer in clinical practice: when and how?. Breast Cancer Res Treat 132(3):775-7, 2012. PMID: 22438051.
31. Chimge NO, Baniwal SK, Luo J, Coetzee S, Khalid O, Berman BP, Tripathy D, Ellis MJ, Frenkel B. Opposing effects of Runx2 and estradiol on breast cancer cell proliferation: in vitro identification of reciprocally regulated gene signature related to clinical letrozole responsiveness. Clin Cancer Res 18(3):901-11, 2012. e-Pub 2011. PMID: 22147940.
32. Cohen E, Belkora J, Tyler J, Schreiner J, Deering MJ, Grama L, Duggan B, Illi J, Pederson J, Anand A, Teng A, McCreary E, Moore D, Tripathy D, Hogarth M, Lieberman M, Park J, Esserman L. Adoption, acceptability, and accuracy of an online clinical trial matching website for breast cancer. J Med Internet Res 14(4):e97, 2012. e-Pub 2012. PMID: 22784878.
33. Tripathy D. PARP inhibitors: the story is still unfolding. Oncology (Williston Park) 25(11):1028, 1030, 2011. PMID: 22106553.
34. Brufsky AM, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, Tripathy D, Tudor IC, Wang LI, Brammer MG, Shing M, Yood MU, Yardley DA. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res 17(14):4834-43, 2011. PMID: 21768129.
35. Langford DJ, Tripathy D, Paul SM, West C, Dodd MJ, Schumacher K, Miaskowski C. Trajectories of pain and analgesics in oncology outpatients with metastatic bone pain. J Pain 12(4):495-507, 2011. e-Pub 2011. PMID: 21310669.
36. Chimge NO, Baniwal SK, Little GH, Chen YB, Kahn M, Tripathy D, Borok Z, Frenkel B. Regulation of breast cancer metastasis by Runx2 and estrogen signaling: the role of SNAI2. Breast Cancer Res 13(6):R127, 2011. e-Pub 2011. PMID: 22151997.
37. Perez AT, Arun B, Tripathy D, Tagliaferri MA, Shaw HS, Kimmick GG, Cohen I, Shtivelman E, Caygill KA, Grady D, Schactman M, Shapiro CL. A phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer. Breast Cancer Res Treat 120(1):111-8, 2010. PMID: 20054647.
38. Silverstein MJ, Recht A, Lagios MD, Bleiweiss IJ, Blumencranz PW, Gizienski T, Harms SE, Harness J, Jackman RJ, Klimberg VS, Kuske R, Levine GM, Linver MN, Rafferty EA, Rugo H, Schilling K, Tripathy D, Vicini FA, Whitworth PW, Willey SC. Special report: Consensus conference III. Image-detected breast cancer: state-of-the-art diagnosis and treatment. J Am Coll Surg 209(4):504-20, 2009. e-Pub 2009. PMID: 19801324.
39. Block KI, Gyllenhaal C, Tripathy D, Freels S, Mead MN, Block PB, Steinmann WC, Newman RA, Shoham J. Survival impact of integrative cancer care in advanced metastatic breast cancer. Breast J 15(4):357-66, 2009. e-Pub 2009. PMID: 19470134.
40. Tripathy D. Are we hitting the right combination for hormonally sensitive breast cancer?. J Clin Oncol 27(16):2580-2, 2009. e-Pub 2009. PMID: 19380439.
41. Abdul-Ghani MA, Muller FL, Liu Y, Chavez AO, Balas B, Zuo P, Chang Z, Tripathy D, Jani R, Molina-Carrion M, Monroy A, Folli F, Van Remmen H, DeFronzo RA. Deleterious action of FA metabolites on ATP synthesis: possible link between lipotoxicity, mitochondrial dysfunction, and insulin resistance. Am J Physiol Endocrinol Metab 295(3):E678-85, 2008. e-Pub 2008. PMID: 18593850.
42. Rugo H, Shtivelman E, Perez A, Vogel C, Franco S, Tan Chiu E, Melisko M, Tagliaferri M, Cohen I, Shoemaker M, Tran Z, Tripathy D. Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer. Breast Cancer Res Treat 105(1):17-28, 2007. e-Pub 2006. PMID: 17111207.
43. Miaskowski C, Dodd M, West C, Paul SM, Schumacher K, Tripathy D, Koo P. The use of a responder analysis to identify differences in patient outcomes following a self-care intervention to improve cancer pain management. Pain 129(1-2):55-63, 2007. e-Pub 2007. PMID: 17257753.
44. Tripathy D. Cardiac side effects of trastuzumab: lessons learned from targeting cancer pathways. Nat Clin Pract Oncol 4(4):220-1, 2007. e-Pub 2007. PMID: 17342070.
45. Gralow J, Tripathy D. Managing metastatic bone pain: the role of bisphosphonates. J Pain Symptom Manage 33(4):462-72, 2007. PMID: 17397707.
46. Tripathy D. Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: underlying rationale and results of clinical trials. Oncologist 12(4):375-89, 2007. PMID: 17470680.
47. Villars P, Dodd M, West C, Koetters T, Paul SM, Schumacher K, Tripathy D, Koo P, Miaskowski C. Differences in the prevalence and severity of side effects based on type of analgesic prescription in patients with chronic cancer pain. J Pain Symptom Manage 33(1):67-77, 2007. PMID: 17196908.
48. Zhang M, Liu X, Li J, He L, Tripathy D. Chinese medicinal herbs to treat the side-effects of chemotherapy in breast cancer patients. Cochrane Database Syst Rev(2):CD004921, 2007. e-Pub 2007. PMID: 17443560.
49. Deng GE, Cassileth BR, Cohen L, Gubili J, Johnstone PA, Kumar N, Vickers A, Society for Integrative Oncology Executive Committee, Abrams D, Rosenthal D, Sagar S, Tripathy D. Integrative Oncology Practice Guidelines. J Soc Integr Oncol 5(2):65-84, 2007. PMID: 17511932.
50. Koch A, Ellis J, Gyllenhaal C, Tripathy D, Lo C, Oberbaum M, Samuels N, Singer SR, Gupta G, Block KI. Integrative tumor board: metastatic breast cancer. Integr Cancer Ther 5(4):373-90, 2006. PMID: 17183755.
51. Guo J, Zhou AW, Fu YC, Verma UN, Tripathy D, Frenkel EP, Becerra CR. Efficacy of sequential treatment of HCT116 colon cancer monolayers and xenografts with docetaxel, flavopiridol, and 5-fluorouracil. Acta Pharmacol Sin 27(10):1375-81, 2006. PMID: 17007746.
52. Body JJ, Diel IJ, Tripathy D, Bergstrom B. Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results. Eur J Cancer Care (Engl) 15(3):299-302, 2006. PMID: 16882128.
53. McLachlan SA, Cameron D, Murray R, Tripathy D, Bergström B. Safety of oral ibandronate in the treatment of bone metastases from breast cancer : long-term follow-up experience. Clin Drug Investig 26(1):43-8, 2006. PMID: 17163234.
54. Silverstein MJ, Lagios MD, Recht A, Allred DC, Harms SE, Holland R, Holmes DR, Hughes LL, Jackman RJ, Julian TB, Kuerer HM, Mabry HC, McCready DR, McMasters KM, Page DL, Parker SH, Pass HA, Pegram M, Rubin E, Stavros AT, Tripathy D, Vicini F, Whitworth PW. Image-detected breast cancer: state of the art diagnosis and treatment. J Am Coll Surg 201(4):586-97, 2005. PMID: 16183499.
55. Kwak YT, Li R, Becerra CR, Tripathy D, Frenkel EP, Verma UN. IkappaB kinase alpha regulates subcellular distribution and turnover of cyclin D1 by phosphorylation. J Biol Chem 280(40):33945-52, 2005. e-Pub 2005. PMID: 16103118.
56. Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Tripathy D, Wolverton DS, Rugo HS, Hwang ES, Ewing CA, Hylton NM. MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol 184(6):1774-81, 2005. PMID: 15908529.
57. Overmoyer B, Silverman P, Holder LW, Tripathy D, Henderson IC. Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer. Clin Breast Cancer 6(2):150-7, 2005. PMID: 16001993.
58. Schumacher KL, Koresawa S, West C, Dodd M, Paul SM, Tripathy D, Koo P, Miaskowski C. Qualitative research contribution to a randomized clinical trial. Res Nurs Health 28(3):268-80, 2005. PMID: 15884025.
59. Melisko ME, Hassin F, Metzroth L, Moore DH, Brown B, Patel K, Rugo HS, Tripathy D. Patient and physician attitudes toward breast cancer clinical trials: developing interventions based on understanding barriers. Clin Breast Cancer 6(1):45-54, 2005. PMID: 15899072.
60. Osborne C, Tripathy D. Aromatase inhibitors: rationale and use in breast cancer. Annu Rev Med 56:103-16, 2005. PMID: 15660504.
61. Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, Beitsch PD, Leitch M, Hoover S, Euhus D, Haley B, Morrison L, Fleming TP, Herlyn D, Terstappen LW, Fehm T, Tucker TF, Lane N, Wang J, Uhr JW. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 10(24):8152-62, 2004. PMID: 15623589.
62. Tripathy D, Body JJ, Bergström B. Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials. Clin Ther 26(12):1947-59, 2004. PMID: 15823760.
63. Kim JE, Dodd M, West C, Paul S, Facione N, Schumacher K, Tripathy D, Koo P, Miaskowski C. The PRO-SELF pain control program improves patients' knowledge of cancer pain management. Oncol Nurs Forum 31(6):1137-43, 2004. e-Pub 2004. PMID: 15547636.
64. Body JJ, Diel IJ, Bell R, Pecherstorfer M, Lichinitser MR, Lazarev AF, Tripathy D, Bergström B. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 111(3):306-12, 2004. PMID: 15363874.
65. Tripathy D, Seidman A, Keefe D, Hudis C, Paton V, Lieberman G. Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer. Clin Breast Cancer 5(4):293-8, 2004. PMID: 15507176.
66. Edrington JM, Paul S, Dodd M, West C, Facione N, Tripathy D, Koo P, Schumacher K, Miaskowski C. No evidence for sex differences in the severity and treatment of cancer pain. J Pain Symptom Manage 28(3):225-32, 2004. PMID: 15336334.
67. Hughes LL, Gray RJ, Solin LJ, Robert NJ, Martino S, Tripathy D, Ingle JN, Wood WC, Eastern Cooperative Oncology Group, Southwest Oncology Group, Cancer and Leukemia Group B, North Central Cancer Treatment Group. Efficacy of radiotherapy for ovarian ablation: results of a breast intergroup study. Cancer 101(5):969-72, 2004. PMID: 15329905.
68. Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, Beitsch P, Khan A, Euhus D, Osborne C, Frenkel E, Hoover S, Leitch M, Clifford E, Vitetta E, Morrison L, Herlyn D, Terstappen LW, Fleming T, Fehm T, Tucker T, Lane N, Wang J, Uhr J. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A 101(25):9393-8, 2004. e-Pub 2004. PMID: 15194824.
69. Block KI, Cohen AJ, Dobs AS, Ornish D, Tripathy D. The challenges of randomized trials in integrative cancer care. Integr Cancer Ther 3(2):112-27, 2004. PMID: 15165498.
70. Miaskowski C, Dodd M, West C, Schumacher K, Paul SM, Tripathy D, Koo P. Randomized clinical trial of the effectiveness of a self-care intervention to improve cancer pain management. J Clin Oncol 22(9):1713-20, 2004. PMID: 15117994.
71. Tripathy D, Lichinitzer M, Lazarev A, MacLachlan SA, Apffelstaedt J, Budde M, Bergstrom B, MF 4434 Study Group. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann Oncol 15(5):743-50, 2004. PMID: 15111341.
72. Tripathy D, Slamon DJ, Cobleigh M, Arnold A, Saleh M, Mortimer JE, Murphy M, Stewart SJ. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 22(6):1063-70, 2004. PMID: 15020607.
73. Body JJ, Diel IJ, Lichinitzer M, Lazarev A, Pecherstorfer M, Bell R, Tripathy D, Bergstrom B. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 90(6):1133-7, 2004. PMID: 15026791.
74. Dhindsa S, Tripathy D, Mohanty P, Ghanim H, Syed T, Aljada A, Dandona P. Differential effects of glucose and alcohol on reactive oxygen species generation and intranuclear nuclear factor-kappaB in mononuclear cells. Metabolism 53(3):330-4, 2004. PMID: 15015145.
75. Osborne C, Wilson P, Tripathy D. Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. Oncologist 9(4):361-77, 2004. PMID: 15266090.
76. Tripathy D. Clinical testing of supplementation therapy in early stage breast cancer: pitfalls and opportunities. Integr Cancer Ther 2(2):160-2, 2003. PMID: 15035905.
77. Esteva FJ, Glaspy J, Baidas S, Laufman L, Hutchins L, Dickler M, Tripathy D, Cohen R, DeMichele A, Yocum RC, Osborne CK, Hayes DF, Hortobagyi GN, Winer E, Demetri GD. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol 21(6):999-1006, 2003. PMID: 12637463.
78. West CM, Dodd MJ, Paul SM, Schumacher K, Tripathy D, Koo P, Miaskowski C. The PRO-SELF(c): Pain Control Program--an effective approach for cancer pain management. Oncol Nurs Forum 30(1):65-73, 2003. PMID: 12515985.
79. Tripathy D. Multidisciplinary care for breast cancer: barriers and solutions. Breast J 9(1):60-3, 2003. PMID: 12558678.
80. Cohen I, Tagliaferri M, Tripathy D. Traditional Chinese medicine in the treatment of breast cancer. Semin Oncol 29(6):563-74, 2002. PMID: 12516039.
81. Campbell MJ, Hamilton B, Shoemaker M, Tagliaferri M, Cohen I, Tripathy D. Antiproliferative activity of Chinese medicinal herbs on breast cancer cells in vitro. Anticancer Res 22(6C):3843-52, 2002. PMID: 12553004.
82. Schumacher KL, Koresawa S, West C, Dodd M, Paul SM, Tripathy D, Koo P, Miaskowski C. The usefulness of a daily pain management diary for outpatients with cancer-related pain. Oncol Nurs Forum 29(9):1304-13, 2002. PMID: 12370700.
83. Schumacher KL, Koresawa S, West C, Hawkins C, Johnson C, Wais E, Dodd M, Paul SM, Tripathy D, Koo P, Miaskowski C. Putting cancer pain management regimens into practice at home. J Pain Symptom Manage 23(5):369-82, 2002. PMID: 12007755.
84. Tripathy D. Overview: gemcitabine as single-agent therapy for advanced breast cancer. Clin Breast Cancer 3 Suppl 1:8-11, 2002. PMID: 12057038.
85. Schumacher KL, West C, Dodd M, Paul SM, Tripathy D, Koo P, Miaskowski CA. Pain management autobiographies and reluctance to use opioids for cancer pain management. Cancer Nurs 25(2):125-33, 2002. PMID: 11984100.
86. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20(3):719-26, 2002. PMID: 11821453.
87. Miaskowski C, Mack KA, Dodd M, West C, Paul SM, Tripathy D, Koo P, Schumacher K, Facione N. Oncology outpatients with pain from bone metastasis require more than around-the-clock dosing of analgesics to achieve adequate pain control. J Pain 3(1):12-20, 2002. PMID: 14622849.
88. Miaskowski C, Dodd MJ, West C, Paul SM, Tripathy D, Koo P, Schumacher K. Lack of adherence with the analgesic regimen: a significant barrier to effective cancer pain management. J Clin Oncol 19(23):4275-9, 2001. PMID: 11731509.
89. Tripathy D. Bisphosphonates in oncology: breast cancer and beyond. Semin Oncol 28(4 Suppl 11):86-91, 2001. PMID: 11544583.
90. Esserman L, Kaplan E, Partridge S, Tripathy D, Rugo H, Park J, Hwang S, Kuerer H, Sudilovsky D, Lu Y, Hylton N. MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. Ann Surg Oncol 8(6):549-59, 2001. PMID: 11456056.
91. Tagliaferri M, Cohen I, Tripathy D. Complementary and alternative medicine in early-stage breast cancer. Semin Oncol 28(1):121-34, 2001. PMID: 11254871.
92. Vogel C, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Genentech H0650 study investigators. First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report. Eur J Cancer 37 Suppl 1:S25-9, 2001. PMID: 11167088.
93. Rugo H, Tripathy D.. New developments in cancer therapeutics targeting HER2/neu and other growth factor receptors. Biotechnology International III:203-221, 2001.
94. Sepucha KR, Belkora JK, Tripathy D, Esserman LJ. Building bridges between physicians and patients: results of a pilot study examining new tools for collaborative decision making in breast cancer. J Clin Oncol 18(6):1230-8, 2000. PMID: 10715292.
95. Benz C and Tripathy D.. ErbB2 overexpression in breast cancer: Biology and clinical translation. J Women’s Cancer 2(1):33-40, 2000.
96. 15. Park JW, Tripathy D, Campbell MJ, Esserman LJ. Biological therapy of breast cancer. BioDrugs 14(4):221-246, 2000.
97. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17(9):2639-48, 1999. PMID: 10561337.
98. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol 26(4 Suppl 12):78-83, 1999. PMID: 10482197.
99. Tripathy D. Breast cancer advocacy in clinical care. Breast Dis 10(5-6):3-14, 1998. PMID: 15687580.
100. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16(8):2659-71, 1998. PMID: 9704716.
101. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14(3):737-44, 1996. PMID: 8622019.
102. Mort EA, Esserman L, Tripathy D, Hillner BE, Houghton J, Bunker JP, Baum M.. Diagnosis and management of early-stage breast cancer. J Clinical Outcomes Management 2:25-42, 1995.
103. Tripathy D. How long should adjuvant tamoxifen be continued?. Oncology (Williston Park) 8(10):25-33; discussion 33, 37-8, 1994. PMID: 7803214.
104. Tripathy D, Henderson IC. Systemic adjuvant therapy for breast cancer. Curr Opin Oncol 4(6):1041-9, 1992. PMID: 1457518.
105. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, Osborne CK. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24(2):85-95, 1992. PMID: 8095168.
106. Tripathy D, Coleman RA, Vidaillet HJ, Steenbergen C, Hirschhorn K, Packer DL. Complete heart block with myocardial membrane-bound glycogen and normal peripheral alpha-glucosidase activity. Ann Intern Med 109(12):985-7, 1988. PMID: 3057987.